Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Acorda acquires PD-focused Biotie for $363mm

Executive Summary

Acorda Therapeutics Inc. acquired all outstanding Nasdaq Helsinki-listed shares and Nasdaq (US)-listed American Depositary Shares (ADSs) of Finnish biotech Biotie Therapies Corp. (neurodegenerative and psychiatric disease therapeutics) for $363mm, over 20 times Biotie's 2014 revenues of $18mm.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies